The FDA intends to expand its use of remote regulatory assessments (RRAs) “across all FDA-regulated products beyond the current COVID-19 public health emergency,” top agency officials said July 22 in announcing the release of draft question-and-answer guidance intended to increase the understanding of RRAs among the industries regulated by the FDA…
